~~<i id='13A42E4BBC'><strike id='13A42E4BBC'><tt id='13A42E4BBC'><pre id='13A42E4BBC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：fashion 2025-09-06 03:53:18 - browse：86532

Bruce Broussard. -- health business coverage from STAT — Humana CEO Bruce Broussard Jason DeCrow/AP

Bruce Broussard, CEO of health insurance giant Humana, will step down next year after leading the company for more than a decade.

Humana named Jim Rechtin — who is the CEO of Envision Healthcare, the controversial physician staffing firm that is working its way through bankruptcy — as Broussard’s replacement. Rechtin will serve as president and chief operating officer starting Jan. 8 and then take over as CEO in the “latter half of 2024,” the company said in a news release.

Humana’s stock fell by more than 2% on the news Wednesday morning.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

explore

Wikipedia

focus

leisure time

hotspot

entertainment

LaurenGavronwalkingwithprostheticinalabattheUniversityofPittsburgh.CourtesyNathanLanger/UPMC&Pit

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

FDA needs staff influx to meet gene therapy needs, Marks says

The woman behind the Dana Farber

John Green on his newest strategy for fighting tuberculosis

focus

Wikipedia

explore

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Apple is now the first public company to be valued at $3 trillion

CMS should re

Moonlake's readout produced a cash windfall. Risks remain

Patients' immediate access to test results puts radiologists in a bind

What does generative AI mean for health care? We asked experts

Readout Newsletter: Bristol, Sangamo, Gilead, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

How to save health care price transparency rules

RaDonda Vaught links Vanderbilt hospital issues to patient death

Pushing for an NIH office for post

Roche to buy Carmot Therapeutics, developer of obesity drugs

John Green on his newest strategy for fighting tuberculosis

How many hemophilia patients actually want gene therapy?

focus

leisure time

hotspot

entertainment